<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>65-ANTIPURINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPURINES" code="ANTIPUR" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Decrease of the effect of the Vitamin K antagonist due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K antagonist at the beginning of the treatment with the immuno-inhibitor and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>65-ANTIPURINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPURINES" code="ANTIPUR" /></DRUG1>
<DRUG2>
<CLASS name="DERIVATIVES OF AMINOSALICYLIC ACID (ASA)" code="A07EC-001" /></DRUG2>
<DESCRIPTION>Risk of increase of the myelotoxicity of the immunoinhibitor, by inhibition of its hepatic metabolism by the ASA derivative, especially with patients presenting a partial deficit of thiopurine methyltransferase (TPMT)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>65-ANTIPURINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPURINES" code="ANTIPUR" /></DRUG1>
<DRUG2>
<CLASS name="XANTHINE OXYDASE INHIBITORS" code="M04AA0" /></DRUG2>
<DESCRIPTION>Possibly serious medullary insufficiency</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>65-ANTIPURINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPURINES" code="ANTIPUR" /></DRUG1>
<DRUG2>
<DRUG name="RIBAVIRIN" rxcui="9344">
<ATC code="J05AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risks of serious undesirable effects, due to inhibition of the metabolism of the immunoinhibitor by the ribavirin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
